Comerica Bank Sells 22,808 Shares of Abbott Laboratories $ABT

Comerica Bank trimmed its holdings in Abbott Laboratories (NYSE:ABT) by 2.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 765,043 shares of the healthcare product maker’s stock after selling 22,808 shares during the period. Comerica Bank’s holdings in Abbott Laboratories were worth $102,470,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Carr Financial Group Corp grew its holdings in shares of Abbott Laboratories by 2.0% during the 3rd quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock worth $520,000 after purchasing an additional 76 shares in the last quarter. Tortoise Investment Management LLC increased its position in shares of Abbott Laboratories by 10.7% in the second quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker’s stock worth $108,000 after purchasing an additional 77 shares during the period. Gemmer Asset Management LLC raised its stake in Abbott Laboratories by 2.9% in the third quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock valued at $368,000 after purchasing an additional 78 shares in the last quarter. Global Financial Private Client LLC lifted its position in Abbott Laboratories by 3.3% during the third quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock worth $331,000 after purchasing an additional 79 shares during the period. Finally, Citizens & Northern Corp grew its stake in Abbott Laboratories by 0.4% during the third quarter. Citizens & Northern Corp now owns 21,875 shares of the healthcare product maker’s stock worth $2,930,000 after buying an additional 79 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Buying and Selling

In other news, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The shares were bought at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the acquisition, the director directly owned 6,738,817 shares in the company, valued at $732,711,572.41. The trade was a 0.15% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the transaction, the executive vice president directly owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. The trade was a 0.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 3,055 shares of company stock worth $353,097 in the last ninety days. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Trading Down 0.1%

ABT opened at $107.99 on Friday. The company has a market cap of $187.66 billion, a P/E ratio of 29.03, a PEG ratio of 1.72 and a beta of 0.74. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The company’s 50 day moving average is $114.58 and its 200-day moving average is $123.91. Abbott Laboratories has a 1-year low of $105.27 and a 1-year high of $139.06.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.50. The business had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the company earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is 67.74%.

Analysts Set New Price Targets

Several equities analysts have recently commented on ABT shares. Sanford C. Bernstein dropped their target price on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Piper Sandler reduced their price target on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research report on Friday, January 23rd. Royal Bank Of Canada decreased their price objective on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Evercore lowered their price objective on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Finally, Barclays reduced their target price on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating on the stock in a report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $136.16.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.